Tiffany A. Traina, MD

Articles

HER2 Dual Blockade in Early Stage HER2+ Breast Cancer

June 27th 2022

Shared insight on the optimal use of HER2 dual-blockade strategies in patients with early stage HER2+ breast cancer.

Early Stage HER2+ Breast Cancer: Overview of Adjuvant Treatment

June 27th 2022

Expert oncologists review adjuvant treatment strategies in early stage HER2+ breast cancer and consider when observation alone would be appropriate.

Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen

June 22nd 2022

Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.

Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC

June 22nd 2022

A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.

Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

June 15th 2022

Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.

Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

June 15th 2022

Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.

Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

June 8th 2022

Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.

Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

June 8th 2022

Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.

Patient Profile 2: Clinical Utility of the HER2CLIMB Regimen for HER2+ mBC

June 1st 2022

Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.

Patient Profile 2: How Should T-DM1 Be Sequenced in HER2+ mBC?

June 1st 2022

Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.

Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

May 26th 2022

Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.

Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

May 26th 2022

Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.

Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

May 19th 2022

Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

May 19th 2022

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

Dr. Traina on the Effects of Elacestrant in ER+, HER2- Breast Cancer

March 21st 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.

Dr. Traina on Results of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 1st 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Managing TRAEs Associated With Novel HER2+ MBC Therapies

November 22nd 2021

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

Dr. Traina on the FDA Approval of Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer

July 12th 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses patient conversations regarding extended adjuvant therapy with neratinib (Nerlynx) in early-stage HER2-positive breast cancer.

Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

March 19th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).